Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Inari Medical Temettü

Temettü kriter kontrolleri 0/6

Inari Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.98
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Investors Interested In Inari Medical, Inc.'s (NASDAQ:NARI) Revenues

Sep 23

Inari Medical: A Touch Of Uncertainty And Overvaluation

Jul 05

At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List?

Jun 18

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

May 23

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

May 02

Inari Medical: Buy On Growing TAM

Mar 27

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Mar 08

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jul 25

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Jun 18

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues

Apr 17

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Dec 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NARI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NARI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Inari Medical Piyasaya Karşı Temettü Getirisi

NARI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NARI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (NARI) (3 yıla kadar)	0%

Önemli Temettü: NARI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NARI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NARI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NARI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Inari Medical Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Investors Interested In Inari Medical, Inc.'s (NASDAQ:NARI) Revenues

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. Announces Peerless Data to Be Presented During the Late-Breaking Clinical Trial Sessions At Tct2024

Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Inari Medical, Inc. Announces CFO Changes

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Chief Medical Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Now 22% overvalued after recent price rise

Inari Medical: A Touch Of Uncertainty And Overvaluation

CEO, President & Director notifies of intention to sell stock

Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc

At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List?

Chief Financial Officer notifies of intention to sell stock

Director notifies of intention to sell stock

Now 22% overvalued

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

Chief Financial Officer exercised options and sold US$273k worth of stock

Grant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc., William Hoffman, Andrew Hykes, and Mitch C. Hill on Behalf of Institutional Investor

Consensus EPS estimates fall by 73%, revenue upgraded

Inari Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 7.4% to US$66.00

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Inari Medical, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Chief Financial Officer exercised options and sold US$243k worth of stock

Inari Medical, Inc. Appoints Tim Benner as Senior Vice President of U.S. Sales

Inari Medical: Buy On Growing TAM

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc., Annual General Meeting, Apr 24, 2024

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Consensus EPS estimates fall by 325%

Price target decreased by 7.5% to US$76.50

Full year 2023 earnings: EPS misses analyst expectations

Inari Medical, Inc. Provides Revenue Guidance for the Full Year 2024

Inari Medical, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Consensus EPS estimates fall by 16%

Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024

Chief Financial Officer exercised options and sold US$405k worth of stock

Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)?

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

CEO, President & Director recently sold US$2.2m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) completed the acquisition of LimFlow SA.

CEO, President & Director notifies of intention to sell stock

Independent Chair of the Board recently bought US$3.0m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) agreed to acquire LimFlow SA for $415 million.

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI)

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business

Chief Financial Officer exercised options and sold US$438k worth of stock

CEO, President & Director recently sold US$2.4m worth of stock

CEO, President & Director notifies of intention to sell stock

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Inari Medical, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Chief Financial Officer exercised options and sold US$363k worth of stock

Inari Medical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. Announces Commercial Launch of Revcore and Triever16 Curve, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism

Inari Medical, Inc Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

Director recently sold US$5.7m worth of stock

Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 58%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues